Single-cell epigenomic and trancriptional dissection of sex-specific differences in Alzheimer?s Disease

Information

  • Research Project
  • 10300867
  • ApplicationId
    10300867
  • Core Project Number
    R01AG074003
  • Full Project Number
    1R01AG074003-01
  • Serial Number
    074003
  • FOA Number
    RFA-AG-21-029
  • Sub Project Id
  • Project Start Date
    9/30/2021 - 2 years ago
  • Project End Date
    5/31/2026 - 2 years from now
  • Program Officer Name
    YUAN, JEAN
  • Budget Start Date
    9/30/2021 - 2 years ago
  • Budget End Date
    5/31/2022 - a year ago
  • Fiscal Year
    2021
  • Support Year
    01
  • Suffix
  • Award Notice Date
    9/24/2021 - 2 years ago

Single-cell epigenomic and trancriptional dissection of sex-specific differences in Alzheimer?s Disease

Abstract Alzheimer?s disease (AD) is a devastating neurodegenerative disorder that leads to dramatic effects on the affected individuals and their families. While the characterization of the genetic contribution to AD and underlying molecular mechanisms have advanced the understanding of the disease in recent years, studies show that sex differences account for much of the observed differences in risk, progression, and severity across individuals. Here, we directly dissect the contribution of sex-specific variation down to the region- specific and cell-type-specific molecular basis by systematic profiling, computational integration, and experimental validation of the transcriptional, epigenomic, and genetic signatures across individuals, brain regions, and cell types. In Aim 1, we use genetic, epigenomic, and transcriptional profiles, generating millions of single-cell (sc) level maps using scRNA-seq and scATAC-seq across human and mouse samples of varying ages and genetic risk status. In Aim 2, we analyze the resulting datasets in the context of known AD genetic risk variation and underlying molecular mechanisms, enabling us to discover and converge variants, regulatory regions, genes, pathways, cell types, and brain regions to functional, causal mechanisms that drive sex-related differences. In Aim 3, we use our well-established mouse and iPSC models to test our predicted mechanisms with both high-throughput and cell-type specific assays. The resulting datasets, computational predictions, and experimentally-supported mechanisms will shed light on the sex-related differences of AD and will help deepen our understanding the disease in general as we develop more personalized therapeutic approaches in treating AD.

IC Name
NATIONAL INSTITUTE ON AGING
  • Activity
    R01
  • Administering IC
    AG
  • Application Type
    1
  • Direct Cost Amount
    716072
  • Indirect Cost Amount
    360844
  • Total Cost
    1076916
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    866
  • Ed Inst. Type
    BIOMED ENGR/COL ENGR/ENGR STA
  • Funding ICs
    NIA:1076916\
  • Funding Mechanism
    Non-SBIR/STTR RPGs
  • Study Section
    ZAG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    MASSACHUSETTS INSTITUTE OF TECHNOLOGY
  • Organization Department
    ENGINEERING (ALL TYPES)
  • Organization DUNS
    001425594
  • Organization City
    CAMBRIDGE
  • Organization State
    MA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    021421029
  • Organization District
    UNITED STATES